Jyotirmoy Dey

975 total citations
20 papers, 573 citations indexed

About

Jyotirmoy Dey is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Statistics and Probability. According to data from OpenAlex, Jyotirmoy Dey has authored 20 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Statistics and Probability. Recurrent topics in Jyotirmoy Dey's work include Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Hedgehog Signaling Pathway Studies (3 papers). Jyotirmoy Dey is often cited by papers focused on Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Hedgehog Signaling Pathway Studies (3 papers). Jyotirmoy Dey collaborates with scholars based in United States, France and United Kingdom. Jyotirmoy Dey's co-authors include Aleodor A. Andea, Daniel W. Visscher, Volkan Adsay, Hind Nassar, Tracie Wallis, Lisa A. Newman, David L. Bouwman, Wael Sakr, David J. Grignon and Shijie Sheng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Jyotirmoy Dey

20 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jyotirmoy Dey United States 11 249 230 151 117 98 20 573
Daisuke Takabatake Japan 15 208 0.8× 154 0.7× 357 2.4× 188 1.6× 66 0.7× 45 688
Dimitrios Tryfonopoulos Greece 12 119 0.5× 55 0.2× 269 1.8× 176 1.5× 50 0.5× 46 627
Saverio Danese Italy 16 199 0.8× 99 0.4× 408 2.7× 228 1.9× 50 0.5× 31 880
Antonio Marrazzo Italy 14 231 0.9× 91 0.4× 282 1.9× 151 1.3× 34 0.3× 39 724
WJ Gradishar United States 15 211 0.8× 58 0.3× 443 2.9× 175 1.5× 34 0.3× 48 718
A. Vindevoghel Belgium 10 474 1.9× 118 0.5× 647 4.3× 134 1.1× 56 0.6× 23 868
Eddie Reed United States 13 100 0.4× 248 1.1× 326 2.2× 323 2.8× 36 0.4× 25 791
Paul T. Adams United States 10 275 1.1× 63 0.3× 435 2.9× 141 1.2× 41 0.4× 15 611
Fernando Lara-Medina Mexico 17 411 1.7× 145 0.6× 487 3.2× 201 1.7× 39 0.4× 40 906
P.-E. Jönsson Sweden 11 280 1.1× 137 0.6× 340 2.3× 111 0.9× 27 0.3× 23 623

Countries citing papers authored by Jyotirmoy Dey

Since Specialization
Citations

This map shows the geographic impact of Jyotirmoy Dey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jyotirmoy Dey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jyotirmoy Dey more than expected).

Fields of papers citing papers by Jyotirmoy Dey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jyotirmoy Dey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jyotirmoy Dey. The network helps show where Jyotirmoy Dey may publish in the future.

Co-authorship network of co-authors of Jyotirmoy Dey

This figure shows the co-authorship network connecting the top 25 collaborators of Jyotirmoy Dey. A scholar is included among the top collaborators of Jyotirmoy Dey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jyotirmoy Dey. Jyotirmoy Dey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gould, A. Lawrence, R. Keith Campbell, John W. Loewy, et al.. (2022). A framework for assessing the impact of accelerated approval. PLoS ONE. 17(6). e0265712–e0265712. 4 indexed citations
2.
Bumma, Naresh, Joshua Richter, Jason Brayer, et al.. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood. 140(Supplement 1). 10140–10141. 29 indexed citations
3.
Dey, Jyotirmoy, et al.. (2022). Zinc‐ bis (imino)pyridine Complexes as Catalysts for Azide‐Alkyne Cycloaddition in Water. ChemistrySelect. 7(48). 2 indexed citations
4.
Bhattacharya, Sudipta & Jyotirmoy Dey. (2022). Assessing Contribution of Treatment Phases through Tipping Point Analyses via Counterfactual Elicitation Using Rank Preserving Structural Failure Time Models. Statistics in Biopharmaceutical Research. 15(3). 661–674. 1 indexed citations
5.
Manitz, Juliane, Hannes Buchner, Evgeny Degtyarev, et al.. (2021). Estimands for overall survival in clinical trials with treatment switching in oncology. Pharmaceutical Statistics. 21(1). 150–162. 16 indexed citations
6.
Singh, Ashish, Parul Verma, Debabrata Samanta, et al.. (2021). Stabilization of ultra-small gold nanoparticles in a photochromic organic cage: modulating photocatalytic CO2 reduction by tuning light irradiation. Journal of Materials Chemistry A. 9(9). 5780–5786. 37 indexed citations
7.
Chen, Kun, et al.. (2020). Comparison of survival distributions in clinical trials: A practical guidance. Clinical Trials. 17(5). 507–521. 7 indexed citations
8.
Ocampo, Clara B., Jun Wu, Jyotirmoy Dey, et al.. (2019). P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress. Journal of Thoracic Oncology. 14(10). S646–S646. 3 indexed citations
9.
Dey, Jyotirmoy, et al.. (2018). Power Analysis of Collapsed Ordered Categories with Application to Cancer Data. Calcutta Statistical Association Bulletin. 70(2). 87–95. 1 indexed citations
10.
Heerspink, Hiddo J.L., Dennis L. Andress, George L. Bakris, et al.. (2018). Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obesity and Metabolism. 20(6). 1369–1376. 58 indexed citations
11.
12.
13.
Geoerger, Birgit, Isabelle Aerts, Michela Casanova, et al.. (2012). A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 9519–9519. 21 indexed citations
14.
Tawbi, Hussein A., Jordi Rodón, Reinhard Dummer, et al.. (2011). Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation.. Journal of Clinical Oncology. 29(15_suppl). 3062–3062. 9 indexed citations
15.
Rodón, Jordi, José Baselga, Hussein A. Tawbi, et al.. (2010). A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2500–2500. 27 indexed citations
16.
Valéri, Antoine, Gaëlle Fromont, Wael Sakr, et al.. (2005). High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. Urologic Oncology Seminars and Original Investigations. 23(2). 87–92. 4 indexed citations
17.
Powell, Isaac J., Susan Land, Jyotirmoy Dey, et al.. (2005). The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 103(3). 528–537. 23 indexed citations
18.
Andea, Aleodor A., Tracie Wallis, Lisa A. Newman, et al.. (2002). Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer. 94(5). 1383–1390. 107 indexed citations
19.
Pierson, Christopher R., et al.. (2002). Maspin is up‐regulated in premalignant prostate epithelia. The Prostate. 53(4). 255–262. 45 indexed citations
20.
Nassar, Hind, et al.. (2001). Clinicopathologic Analysis of Invasive Micropapillary Differentiation in Breast Carcinoma. Modern Pathology. 14(9). 836–841. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daisuke Takabatake Breakdown of academic impact, for papers by Dimitrios Tryfonopoulos Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by Antonio Marrazzo Breakdown of academic impact, for papers by WJ Gradishar Breakdown of academic impact, for papers by A. Vindevoghel Breakdown of academic impact, for papers by Eddie Reed Breakdown of academic impact, for papers by Paul T. Adams Breakdown of academic impact, for papers by Fernando Lara-Medina Breakdown of academic impact, for papers by P.-E. Jönsson
Rankless by CCL
2026